AngioDynamics (NASDAQ:ANGO) Announces Earnings Results, Misses Estimates By $0.01 EPS

Share on StockTwits

AngioDynamics (NASDAQ:ANGO) released its quarterly earnings results on Wednesday. The medical instruments supplier reported $0.25 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.01), Morningstar.com reports. AngioDynamics had a return on equity of 5.58% and a net margin of 17.06%. The business had revenue of $96.30 million for the quarter, compared to the consensus estimate of $92.34 million. During the same period in the prior year, the business posted $0.20 earnings per share. AngioDynamics’s revenue was up 9.1% compared to the same quarter last year. AngioDynamics updated its FY 2020 guidance to $0.25-0.30 EPS and its FY20 guidance to $0.25-0.30 EPS.

ANGO stock opened at $21.89 on Friday. The company has a current ratio of 4.30, a quick ratio of 1.70 and a debt-to-equity ratio of 0.20. AngioDynamics has a 12 month low of $18.11 and a 12 month high of $25.48. The company has a market cap of $783.77 million, a price-to-earnings ratio of 26.37 and a beta of 0.69. The firm has a 50-day moving average price of $19.57.

A number of hedge funds have recently added to or reduced their stakes in ANGO. Oregon Public Employees Retirement Fund bought a new position in AngioDynamics in the 4th quarter valued at about $284,000. PNC Financial Services Group Inc. increased its holdings in AngioDynamics by 28.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 5,315 shares of the medical instruments supplier’s stock valued at $107,000 after buying an additional 1,181 shares during the period. BlackRock Inc. increased its holdings in AngioDynamics by 2.8% in the 4th quarter. BlackRock Inc. now owns 5,918,221 shares of the medical instruments supplier’s stock valued at $119,134,000 after buying an additional 158,932 shares during the period. Texas Permanent School Fund increased its holdings in AngioDynamics by 4.1% in the 4th quarter. Texas Permanent School Fund now owns 24,292 shares of the medical instruments supplier’s stock valued at $489,000 after buying an additional 964 shares during the period. Finally, Advisor Group Inc. increased its holdings in AngioDynamics by 21.4% in the 4th quarter. Advisor Group Inc. now owns 3,405 shares of the medical instruments supplier’s stock valued at $68,000 after buying an additional 601 shares during the period. 98.46% of the stock is currently owned by hedge funds and other institutional investors.

ANGO has been the topic of a number of recent research reports. BidaskClub raised shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a research report on Friday. TheStreet lowered shares of Upland Software from a “b-” rating to a “c+” rating in a research report on Wednesday. ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. Finally, Zacks Investment Research raised shares of Investar from a “hold” rating to a “buy” rating and set a $27.00 price target on the stock in a research report on Tuesday, June 4th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $21.50.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

See Also: How to interpret Moving Average Convergence Divergence (MACD)

Earnings History for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.